News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Announcement of prospectus regarding PledPharma’s rights issue

November 11, 2016

PledPharma AB
Company Announcement

Announcement of prospectus regarding PledPharma’s rights issue

Stockholm, 2016-11-11 18:34 CET (GLOBE NEWSWIRE) -- 
The Board of Directors of PledPharma AB (publ) (“PledPharma” or the “Company”)
has prepared a prospectus for the purpose of the rights issue, which was
announced on 20 October 2016. 


The prospectus has been approved by and registered with the Swedish Financial
Supervisory Authority (Sw. Finansinspektionen). The prospectus is now available
on PledPharma’s website (www.pledpharma.se) and Carnegie Investment Bank AB's
website (www.carnegie.se) and will be available at the Swedish Financial
Supervisory Authority's website (www.fi.se). 

For further information, please contact:

Jacques Näsström, CEO, +46 73 713 09 79

Håkan Åström, Chairman of the board, +46 70 374 72 13

For more information about the Company, please visit www.pledpharma.se

Stockholm, 11 November 2016
PledPharma AB (publ)



About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® reduces nerve damage
associated with chemotherapy and positive results from the Phase IIb study
PLIANT were presented during the spring of 2015. The drug candidate Aladote® is
being developed to reduce the risk of acute liver failure associated with
acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First
North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80
00). For more information, see www.pledpharma.se 

This information is information that PledPharma AB (publ) is obliged to make
public pursuant to the Securities Markets Act. The information was submitted
for publication, through the agency of the contact person set out above, on
November 11, 2016. 


IMPORTANT INFORMATION

The information in this press release does not contain or constitute an
invitation or offer from PledPharma AB (publ) (”PledPharma”), Carnegie
Investment Bank AB (publ) or any other person to acquire, subscribe for or
otherwise trade in shares, subscription rights or other securities in
PledPharma AB. An invitation to relevant persons to subscribe for shares in
PledPharma will only be made through the prospectus that PledPharma intends to
publish on its website when such prospectus has been approved and registered by
the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The
prospectus will contain, among other things, information on risk factors
associated with the company’s business or the securities referred to in this
press release, financial statements as well as information regarding the
company’s board of directors. This press release has not been approved by any
regulatory authority and does not constitute a prospectus. Investors should not
subscribe for or purchase any securities referred to in this press release,
unless such investment decision is based on the information contained in the
prospectus that will be published by PledPharma. 

The information in this press release is not intended to be, and may not be,
announced, published or distributed, directly or indirectly, in the United
States, Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore, South
Africa or any other country where such action would be illegal or is wholly or
partially subject to legal restrictions or where such action would require
additional prospectuses, other offer documentation, registrations or other
actions in addition to what follows from Swedish law. The recipient of this
press release is responsible for that the recipient’s use of this press release
and the information contained herein is in accordance with applicable laws in
any relevant jurisdictions. 

If and to the extent that this press release is communicated in any European
Economic Area (EEA) member state that has implemented Directive 2003/71/EC in
its current wording (together with any applicable implementing measures in such
member state, the "Prospectus Directive"), this press release is only addressed
to and directed at persons in such EEA member state who meet the criteria for
an exemption from the obligation to draw up and publish a prospectus as
implemented in such member state, such as for example qualified investors as
defined in the Prospectus Directive. 

This press release does not, and will not, contain or constitute an invitation
or offer to acquire or subscribe for securities in the United States. The
securities referred to in this press release may not be offered or sold in the
United States without registration or an exemption from registration in
accordance with the United States Securities Act of 1933 in its current wording
(“Securities Act”). PledPharma does not intend to register any securities
referred to herein in the United States or to make a public offering of the
securities in the United States. 

This press release, and any other material concerning the securities referred
to herein, is only being distributed to and directed at (i) persons outside the
United Kingdom and Northern Ireland (ii) persons with professional experience
in matters relating to investments who fall within the scope of Article 19(5)
of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005, as amended (the "Financial Promotion Order"), or (iii) high net worth
companies and other persons to whom this press release may otherwise be
lawfully communicated pursuant to Article 49(2)(a) to (d) of the Financial
Promotion Order. All persons in (i) – (iii) above are together being referred
to as "relevant persons". The securities referred to in this press release are
only available to relevant persons, and any invitation, offer or agreement
regarding the subscription or acquisition of such securities is directed
exclusively at such relevant persons. A person who is not a relevant person may
not act on or rely upon this press release or the information contained herein.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]